https://doi.org/10.4046/trd.2016.79.1.14. PMID: 26770230. PMCID: PMC4701789.

2. Morice A.H., Millqvist E., Belvisi M.G. et al. Expert opinion on the cough hypersensitivity syndrome in respiratory medicine. Eur Respir J. 2014; 44(5): 1132–48.

https://doi.org/10.1183/09031936.00218613. PMID: 25142479.

3. Чучалин А.Г., Абросимов В.Н. Кашель. 4-е издание, переработанное и дополненное. М.: ГЭОТАР-Медиа. 2017: 150 с. (Chuchalin A.G., Abrosimov V.N. Cough. 4th edition, revised and expanded. Moscow: GEOTAR-Media. 2017; 150 pp. (In Russ.)). ISBN: 978-5-9704-4293-7.

4. GOLD Report 2023: Global strategy for prevention, diagnosis and management of COPD. URL: https://goldcopd.org/2023-gold-report-2 (date of access – 01.03.2024).

5. Клинические рекомендации. Хроническая обструктивная болезнь легких. Российское респираторное общество. Рубрикатор клинических рекомендаций Минздрава России. 2021. ID: 603. Доступ: https://cr.minzdrav.gov.ru/schema/603_2 (дата обращения – 01.03.2024). (Clinical guidelines. Chronic obstructive pulmonary disease. Russian Respiratory Society. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2021. ID: 603. URL: https://cr.minzdrav.gov.ru/schema/603_2 (date of access – 01.03.2024) (In Russ.)).

6. Miravitlles M., Anzueto A. Role of infection in exacerbations of chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2015; 21(3): 278–83.

https://doi.org/10.1097/MCP.0000000000000154. PMID: 25719955.

7. Morris D.E., Cleary D.W., Clarke S.C. Secondary bacterial infections associated with influenza pandemics. Frontiers Microbiol. 2017; 8: 1041.

https://doi.org/10.3389/fmicb.2017.0104117. PMID: 28690590. PMCID: PMC5481322.

8. Оковитый С.В., Зайцев А.А., Анисимова Н.А. Фармакодинамические подходы к применению мукоактивных препаратов. Лечащий врач. 2020; (10): 6–10. (Okovity S.V., Zaitsev A.A., Anisimova N.A. Pharmacodynamic approaches to the use of mucoactive drugs. Lechaschi vrach = Attending Physician. 2020; (10): 6–10 (In Russ.)).

https://doi.org/10.26295/OS.2020.62.62.001. EDN: CNBKRI.

9. Linssen R.S.N., Ma J., Bem R.A., Rubin B.K. Rational use of mucoactive medications to treat pediatric airway disease. Paediatr Respir Rev. 2020: 36: 8–14.

https://doi.org/10.1016/j.prrv.2020.06.007. PMID: 32653467. PMCID: PMC7297155.

10. Calzetta L., Matera M.G., Rogliani P., Cazzola M. Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease. Expert Rev Respir Med. 2018; 12(8): 693–708.

https://doi.org/10.1080/17476348.2018.1495562. PMID: 29972340.

11. Mokhtari V., Afsharian P., Shahhoseini M. et al. A Review on various uses of N-acetyl cysteine. Cell J. 2017; 19(1): 11–17.

https://doi.org/10.22074/cellj.2016.4872. PMID: 28367412. PMCID: PMC5241507.

12. Pei Y., Liu H., Yang Y. et al. Biological activities and potential oral applications of N-acetylcysteine: Progress and prospects. Oxid Med Cell Longev. 2018: 2018: 2835787.

https://doi.org/10.1155/2018/2835787. PMID: 29849877. PMCID: PMC5937417.

13. Dhouib I.E., Jallouli M., Annabi A. et al. A minireview on N-acetylcysteine: An old drug with new approaches. Life Sci. 2016; 151: 359–63.

https://doi.org/10.1016/j.lfs.2016.03.003. PMID: 26946308.

14. (Qu D., Ren X.X., Guo L.Y. et al. Effect of N-acetylcysteine inhalation on ventilator-associated pneumonia caused by biofilm in endotracheal tubes. Zhonghua Er Ke Za Zhi. 2016; 54(4): 278–82 (In Chinese)).

https://doi.org/10.3760/cma.j.issn.0578-1310.2016.04.010. PMID: 27055427.

15. Aruoma O.I., Halliwell B., Hoey B.M., Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med. 1989; 6(6): 593–97.

https://doi.org/10.1016/0891-5849(89)90066-x. PMID: 2546864.

16. Шаненова Ш.Ж., Коптлеуова А.С., Дарбаева К.С. с соавт. Клиническая эффективность N-ацетилцистеина при ХОБЛ. Медицинский журнал Западного Казахстана. 2012; (3): 260. (Shanenova Sh.Zh., Koptleuova A.S., Darbaeva K.S. et al. Clinical effectiveness of N-acetylcysteine in COPD. Meditsinskiy zhurnal Zapadnogo Kazakhstana = Medical Journal of Western Kazakhstan. 2012; (3): 260 (In Russ.)). EDN: UITSWH.

17. Drago L., De Vecchi E., Mattina R. et al. Activity of N-acetyl-L-cysteine against biofilm of Staphylococcus aureus and Pseudomonas aeruginosa on orthopedic prosthetic materials. Int J Artif Organs. 2018; 36(1): 39–46.

https://doi.org/10.5301/ijao.5000135. PMID: 23280076.

18. Княжеская Н.П., Новиков Ю.К., Бобков Е.В. N-ацетилцистеин (Флуимуцил®) в терапии острых и хронических заболеваний органов дыхания. Справочник поликлинического врача. 2012; (4): 56–60. (Knyazheskaya N.P., Novikov Yu.K., Bobkov E.V. N-acetylcysteine (Fluimucil®) in the treatment of acute and chronic respiratory diseases. Spravochnik poloklinicheskogo vracha = Clinician’s Reference Book. 2012; (4): 56–60 (In Russ.)). EDN: SJIKKJ.

19. Tenorio M.C.D.S., Graciliano N.G., Moura F.A. et al. N-Acetylcysteine (NAC): Impacts on human health. Antioxidants (Basel). 2021; 10(6): 967.

https://doi.org/10.3390/antiox10060967. PMID: 34208683. PMCID: PMC8234027.

20. Aldini G., Altomare A., Baron G. et al. N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why. Free Radic Res. 2018; 52(7): 751–62.

https://doi.org/10.1080/10715762.2018.1468564. PMID: 29742938.

21. Fokkens W.J., Lund V.J., Hopkins C. et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020; 58(Suppl S29): 1–464.

https://doi.org/10.4193/Rhin20.600. PMID: 32077450.

22. van den Broek M.F., Gudden C., Kluijfhout W.P. et al. No evidence for distinguishing bacterial from viral acute rhinosinusitis using symptom duration and purulent rhinorrhea: a systematic review of the evidence base. Otolaryngol Head Neck Surg. 2014; 150(4): 533–37.

https://doi.org/10.1177/0194599814522595. PMID: 24515968.

23. Клинические рекомендации. Острый синусит. Национальная медицинская ассоциация оториноларингологов. Рубрикатор клинических рекомендаций Минздрава России. 2021. ID: 313. Доступ: https://cr.minzdrav.gov.ru/schema/313_2 (дата обращения – 01.03.2024). (Clinical guidelines. Acute sinusitis. National Medical Association of Otolaryngologists. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2021. ID: 313. URL: https://cr.minzdrav.gov.ru/schema/313_2 (date of access – 01.03.2024) (In Russ.)).

24. Яковлев С.В., Рафальский В.В., Сидоренко С.В. с соавт. Стратегия и тактика рационального применения антимикробных средств в амбулаторной практике. Евразийские клинические рекомендации. Педиатрия. Consilium medicum. 2017; (1): 17–25. (Yakovlev S.V., Rafalsky V.V., Sidorenko S.V. et al. Strategy and tactics of the rational use of antimicrobial drugs in outpatient practice. Eurasian clinical guidelines. 2016. Pediatriya. Consilium Medicum = Pediatrics. Consilium Medicum. 2017; (1): 17–25. (In Russ.)). EDN: YPSTGH.

25. Flamm R.K., Sader H.S., Jones R.N. Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010. Braz J Infect Dis. 2013; 17(5): 564–72.

https://doi.org/10.1016/j.bjid.2013.02.008. PMID: 23916453. PMCID: PMC9425132.

26. Кривопалов А.А., Рязанцев С.В., Еремин С.А. с соавт. К вопросу о топической антибактериальной терапии острых риносинуситов. Вестник оториноларингологии. 2019; 2: 50–56. (Krivopalov A.A., Ryazantsev S.V., Eremin S.A. et al. On the issue of topical antibacterial therapy of acute rhinosinusitis. Vestnik otorinolaringologii = Bulletin of Otorhinolaryngology. 2019; (2): 50–56 (In Russ.)).

https://doi.org/10.17116/otorino20198402150. EDN: VBNYLI.

27. Martin B.R., Reshamwala G., Short M. Treatment of a woman with Glycyrrhiza glabra for acute sinusitis: A case report. J Chiropr Med. 2018; 17(4): 268–74.

https://doi.org/10.1016/j.jcm.2018.04.005. PMID: 30846920. PMCID: PMC6391234.

28. Яковлев С.В., Елисеева Е.В., Суворова М.П. с соавт. Стратегия и тактика рационального применения антимикробных средств в амбулаторной практике. Евразийские клинические рекомендации, 2016 г. Справочник поликлинического врача. 2017; (1): 6–53. (Yakovlev S., Eliseeva E.V., Suvorova M.P. et al. Strategy and tactics of rational use of antimicrobial agents in outpatient practice. Eurasian Clinical Guidelines. 2016. Spravochnik poloklinicheskogo vracha = Clinician's Reference Book. 2017; (1): 6–53 (In Russ.)). EDN: ZCNDQP.

29. Иванчик Н.В., Сухорукова М.В., Чагарян А.Н. с соавт. In vitro активность тиамфеникола в отношении клинических изолятов Haemophilus influenzae, Streptococcus pneumoniae и Streptococcus pyogenes. Клиническая микробиология и антимикробная химиотерапия. 2021; 23(1): 92–99. (Ivanchik N.V., Sukhorukova M.V., Chagaryan A.N. et al. In vitro activity of thiamphenicol against Haemophilus influenzae, Streptococcus pneumoniae and Streptococcus pyogenes clinical isolates. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya = Clinical Microbiology and Antimicrobial Chemotherapy. 2021; 23(1): 92–99 (In Russ.)).

https://doi.org/10.36488/cmac.2021.1.92-99. EDN: SJKIKA.

30. Авдеев С.Н., Гаращенко Т.И., Геппе Н.А. с соавт. Резолюция совета экспертов по вопросу использования тиамфеникола глицинат ацетилцистеината в лечении внебольничных респираторных инфекций. Клиническая микробиология и антимикробная химиотерапия. 2021; 23(2): 195–196. (Avdeev S.N., Garashchenko T.I., Geppe N.A. et al. Official statements of the board of experts on the use of topical thiamphenicol in patients with communityacquired respiratory infections. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya = Clinical Microbiology and Antimicrobial Chemotherapy. 2021; 23(2): 195–196 (In Russ.)).

https://doi.org/10.36488/cmac.2021.2.195-196. EDN: UJVVVW.

31. Samuni Y., Goldstein S., Dean O.M., Berk M. The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta. 2013; 1830(8): 4117–29.

https://doi.org/10.1016/j.bbagen.2013.04.016. PMID: 23618697.

32. Dinicola S., de Grazia S., Carlomagno G., Pintucci J.P. N-acetylcysteine as powerful molecule to destroy bacterial biofilms. A systematic review. Eur Rev Med Pharmacol Sci. 2020; 18(19): 2942–48. PMID: 25339490.

33. Blasi F., Page C., Rossolini G.M. et al. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respiratory Medicine. 2016; 117: 190–97.

https://doi.org/10.1016/j.rmed.2016.06.015. PMID: 27492531.